Last reviewed · How we verify
NCT07085559
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
EARLY_PHASE1 trial testing Metabolically Armed BCMA CAR-T cells. in Multiple Myeloma (MM) in 36 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 23 June 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 15 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Metabolically Armed BCMA CAR-T cells. — full drug profile →
Conditions studied
- Multiple Myeloma (MM) — all drugs for Multiple Myeloma (MM) →
- Plasma Cell Leukemia (PCL) — all drugs for Plasma Cell Leukemia (PCL) →
- AL Amyloidosis (AL) — all drugs for AL Amyloidosis (AL) →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 19 to 75, any sex, with Multiple Myeloma (MM) or Plasma Cell Leukemia (PCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07085559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma (MM)
Currently open trials in the same condition.
- NCT07342179 — CAR-T Immunomonitoring in Multiple Myeloma (CART I5M) · NA · recruiting
- NCT07101705 — An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin · EARLY_PHASE1 · recruiting
- NCT07051850 — Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies · recruiting
- NCT06767254 — A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence · recruiting
- NCT07088783 — Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients · NA · active not recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07085559 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 25 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing